Cargando…

tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue

The binding sites of antitumor drug doxorubicin (DOX) and its analogue N-(trifluoroacetyl) doxorubicin (FDOX) with tRNA were located, using FTIR, CD, fluorescence spectroscopic methods and molecular modeling. Different binding sites are involved in drug-tRNA adducts with DOX located in the vicinity...

Descripción completa

Detalles Bibliográficos
Autores principales: Agudelo, Daniel, Bourassa, Philippe, Beauregard, Marc, Bérubé, Gervais, Tajmir-Riahi, Heidar-Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726733/
https://www.ncbi.nlm.nih.gov/pubmed/23922696
http://dx.doi.org/10.1371/journal.pone.0069248
_version_ 1782278699368841216
author Agudelo, Daniel
Bourassa, Philippe
Beauregard, Marc
Bérubé, Gervais
Tajmir-Riahi, Heidar-Ali
author_facet Agudelo, Daniel
Bourassa, Philippe
Beauregard, Marc
Bérubé, Gervais
Tajmir-Riahi, Heidar-Ali
author_sort Agudelo, Daniel
collection PubMed
description The binding sites of antitumor drug doxorubicin (DOX) and its analogue N-(trifluoroacetyl) doxorubicin (FDOX) with tRNA were located, using FTIR, CD, fluorescence spectroscopic methods and molecular modeling. Different binding sites are involved in drug-tRNA adducts with DOX located in the vicinity of A-29, A-31, A-38, C-25, C-27, C-28, G-30 and U-41, while FDOX bindings involved A-23, A-44, C-25, C-27, G-24, G-42, G-53, G-45 and U-41 with similar free binding energy (-4.44 for DOX and -4.41 kcal/mol for FDOX adducts). Spectroscopic results showed that both hydrophilic and hydrophobic contacts are involved in drug-tRNA complexation and FDOX forms more stable complexes than DOX with K (DOX-tRNA) = 4.7 (±0.5)×10(4) M(−1) and K (FDOX-tRNA) = 6.3 (±0.7)×10(4) M(−1). The number of drug molecules bound per tRNA (n) was 0.6 for DOX and 0.4 for FDOX. No major alterations of tRNA structure were observed and tRNA remained in A-family conformation, while biopolymer aggregation and particle formation occurred at high drug concentrations.
format Online
Article
Text
id pubmed-3726733
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37267332013-08-06 tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue Agudelo, Daniel Bourassa, Philippe Beauregard, Marc Bérubé, Gervais Tajmir-Riahi, Heidar-Ali PLoS One Research Article The binding sites of antitumor drug doxorubicin (DOX) and its analogue N-(trifluoroacetyl) doxorubicin (FDOX) with tRNA were located, using FTIR, CD, fluorescence spectroscopic methods and molecular modeling. Different binding sites are involved in drug-tRNA adducts with DOX located in the vicinity of A-29, A-31, A-38, C-25, C-27, C-28, G-30 and U-41, while FDOX bindings involved A-23, A-44, C-25, C-27, G-24, G-42, G-53, G-45 and U-41 with similar free binding energy (-4.44 for DOX and -4.41 kcal/mol for FDOX adducts). Spectroscopic results showed that both hydrophilic and hydrophobic contacts are involved in drug-tRNA complexation and FDOX forms more stable complexes than DOX with K (DOX-tRNA) = 4.7 (±0.5)×10(4) M(−1) and K (FDOX-tRNA) = 6.3 (±0.7)×10(4) M(−1). The number of drug molecules bound per tRNA (n) was 0.6 for DOX and 0.4 for FDOX. No major alterations of tRNA structure were observed and tRNA remained in A-family conformation, while biopolymer aggregation and particle formation occurred at high drug concentrations. Public Library of Science 2013-07-29 /pmc/articles/PMC3726733/ /pubmed/23922696 http://dx.doi.org/10.1371/journal.pone.0069248 Text en © 2013 Agudelo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Agudelo, Daniel
Bourassa, Philippe
Beauregard, Marc
Bérubé, Gervais
Tajmir-Riahi, Heidar-Ali
tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
title tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
title_full tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
title_fullStr tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
title_full_unstemmed tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
title_short tRNA Binding to Antitumor Drug Doxorubicin and Its Analogue
title_sort trna binding to antitumor drug doxorubicin and its analogue
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726733/
https://www.ncbi.nlm.nih.gov/pubmed/23922696
http://dx.doi.org/10.1371/journal.pone.0069248
work_keys_str_mv AT agudelodaniel trnabindingtoantitumordrugdoxorubicinanditsanalogue
AT bourassaphilippe trnabindingtoantitumordrugdoxorubicinanditsanalogue
AT beauregardmarc trnabindingtoantitumordrugdoxorubicinanditsanalogue
AT berubegervais trnabindingtoantitumordrugdoxorubicinanditsanalogue
AT tajmirriahiheidarali trnabindingtoantitumordrugdoxorubicinanditsanalogue